It examines the impact of mTOR on podocytes, glomerular mesangial cells, renal tubular epithelial cells, and glomerular endothelial cells—each playing a crucial role in kidney function.

Researchers say study findings have important implications for our understanding of the pathogenesis of obesity and potential therapeutic applications.

Scientists at Southern University of Science and Technology in Shenzhen, China, have identified a new regulator of the mammalian target of rapamycin (mTOR) pathway associated with the growth of ...

Cassava's strong liquidity with $128.6 million in cash supports early-stage development, yet long-term funding needs may lead ...

mTOR inhibitors. Everolimus (Afinitor) is a drug that blocks the mTOR protein and helps stop the growth and spread of cancer cells. PI3K inhibitors. Alpelisib (Piqray) and inavolisib (Itovebi ...

Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an analysis of CELC stock now.

Researchers from SRM Institute of Science and Technology, led by Dr. KN Aruljothi, have published a study in ExRNA ...

Encapsulated rapamycin is expected to prevent disease progression by inhibiting mTOR, a protein kinase that has been shown to be overexpressed in FAP polyps. The Food and Drug Administration (FDA ...

The study reveals that excessive activation of mTOR contributes to kidney injury by inhibiting autophagy, increasing oxidative stress, and promoting inflammation. It examines the impact of mTOR on ...